Candidemia Pipeline Summary

DelveInsight’s, “Candidemia - Pipeline Insight, 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Candidemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Candidemia: Understanding

Candidemia: Overview

Candida spp. are commensal yeasts that normally colonize the skin and mucosal surfaces of the mouth, intestine, and vagina but can become opportunistic pathogens when the host–microbial balance is disrupted. The human mycobiome contributes to immune regulation and metabolic homeostasis and is influenced by factors such as age, diet, antimicrobial exposure, and the environment. Risk factors including central venous catheters, immunosuppression, total parenteral nutrition, and broad-spectrum antibiotic use can promote Candida overgrowth and dissemination into normally sterile tissues, resulting in invasive candidiasis, with candidemia representing its most common form. Candidemia is associated with prolonged hospitalization, increased healthcare costs, and substantial mortality. Although Candida albicans has historically been the predominant bloodstream isolate, non-albicans Candida species are increasingly prevalent and may exhibit distinct antifungal susceptibility profiles. The emergence of multidrug-resistant Candida auris has further complicated disease management, particularly in healthcare settings, highlighting the need for appropriate empiric antifungal therapy followed by species-directed and susceptibility-guided treatment.

Candida is a genus of yeasts belonging to the fungal subphylum Saccharomycotina and comprises numerous species, with Candida albicans being the most common pathogenic species. Candida spp. are commensal organisms that normally colonize human skin and mucosal surfaces, including the mouth, intestine, and vagina. Colonization is common among healthy individuals and varies according to the body site and population, with persistent colonization generally regarded as an important prerequisite for the development of candidemia.

Candida spp. are commensal yeasts that normally inhabit the gastrointestinal tract and the vaginal, oral, and skin microbiomes. Colonization is an important prerequisite for the development of invasive candidiasis and candidemia, particularly when conditions facilitate disruption of mucosal or skin barriers, promote fungal proliferation and biofilm formation, or impair host immune defenses. Key risk factors include indwelling vascular catheters, immunosuppression, gastrointestinal surgery that may facilitate microbial translocation, broad-spectrum antibiotic exposure, and the use of peripheral or total parenteral nutrition and lipid emulsions, all of which can increase the risk of invasive Candida infection.

Conventional blood culture remains the gold standard for diagnosing candidemia, although its sensitivity is limited and results may take several days for organism growth and identification. Once Candida is detected, species identification and antifungal susceptibility testing are essential to guide treatment. Given the limitations of culture, non-culture diagnostic approaches such as ?-D-glucan, molecular assays, and PCR are increasingly used as complementary tools. ?-D-glucan offers high sensitivity but limited specificity because it can detect fungal infections beyond Candida and should therefore not be used as a standalone diagnostic test. The T2Candida assay, an FDA-approved molecular diagnostic, can rapidly detect several major Candida species directly from blood and may facilitate earlier diagnosis and treatment, although its coverage is limited to specific species. PCR-based assays also offer rapid detection and can provide high diagnostic accuracy in certain settings; however, variability among platforms and patient populations and the lack of standardized testing remain important limitations. Overall, combining blood culture with rapid non-culture or molecular diagnostics can improve the timely detection and management of candidemia.

Management of candidemia requires prompt initiation of appropriate antifungal therapy, effective source control, and close monitoring, with infectious disease or clinical microbiology consultation recommended whenever possible. Echinocandins, including anidulafungin, caspofungin, micafungin, and rezafungin, are generally preferred as initial therapy, while liposomal amphotericin B or selected azoles may be considered when echinocandins are unsuitable or resistance is suspected. Source control measures, such as removal of central venous catheters when appropriate, are important, and repeat blood cultures are used to assess clearance and treatment response. Persistent candidemia despite appropriate therapy and source control should prompt evaluation for complications such as endocarditis, abscesses, or other deep-seated infections. Subsequent treatment should be guided by Candida species identification, antifungal susceptibility, clinical response, and the patient's ability to tolerate oral therapy, with stable patients who meet appropriate criteria potentially transitioning to oral fluconazole. Therapy is generally continued for at least two weeks after documented clearance of the bloodstream, provided clinical symptoms have resolved and there is no evidence of neutropenia or deep-seated or metastatic infection.

"Candidemia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Candidemia pipeline landscape is provided which includes the disease overview and Candidemia treatment guidelines. The assessment part of the report embraces, in depth Candidemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Candidemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Candidemia R&D. The therapies under development are focused on novel approaches to treat/improve Candidemia.

Candidemia Emerging Drugs Chapters

This segment of the Candidemia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Candidemia Emerging Drugs

Fosmanogepix: Basilea Pharmaceuticals

Fosmanogepix is a clinical-stage, broad-spectrum antifungal with a novel mechanism of action, demonstrating activity against common Candida and Aspergillus species, including multidrug-resistant pathogens such as Candida auris and Candida glabrata, as well as difficult-to-treat molds including Fusarium, Lomentospora prolificans, Scedosporium, and certain Mucorales species. Both intravenous and oral formulations have been evaluated in clinical studies for candidemia, including C. auris infections, and invasive mold infections. Fosmanogepix has also received FDA Fast Track and Orphan Drug designations across multiple indications and has been designated a Qualified Infectious Disease Product (QIDP). According to company’s pipeline the drug is in Phase III stage of it’s development for the treatment of Candidemia.

Further product details are provided in the report……..

Candidemia: Therapeutic Assessment

This segment of the report provides insights about the different Candidemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Candidemia
• There are approx. 4+ key companies which are developing the therapies for Candidemia. The companies which have their Candidemia drug candidates in the most advanced stage, i.e. Phase II include, Basilea Pharmaceuticals.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Candidemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Candidemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Candidemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Candidemia drugs.

Candidemia Report Insights

• Candidemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Candidemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Candidemia drugs?
• How many Candidemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Candidemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Candidemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Candidemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Basilea Pharmaceuticals
• Jiangsu Hengrui Pharmaceuticals

Key Products

• Fosmanogepix
• HRS9432